



BioLight Life Sciences enters clinical research collaboration with Alexion AstraZeneca Rare Disease to evaluate screening technique for retinal ophthalmic conditions

May 29, 2023

BioLight [TASE: BOLT] is proud to announce that, it has signed a research collaboration agreement with AstraZeneca, Alexion, AstraZeneca Rare Disease, for the conduct of a human clinical feasibility study to evaluate an innovative screening technique with potential to diagnose various retinal ophthalmic conditions.

The study, financed by Alexion and BioLight, will evaluate a screening technique (the “**Technology**”) that analyzes components of the tear film, a fluid layer covering the outer surfaces of the eye. The Technology was licensed from Harvard University. The tests of the tear samples will be analyzed by one of the inventors of the Technology, Prof. Yifat Merbl, currently at the Weizmann Institute of Science. The study will be conducted at the Tel Aviv Medical Center and led by Prof. Anat Loewenstein, Chair of the Ophthalmology department.

Yaacov Michlin, CEO of BioLight states "*Retinal disease affects the vision of hundreds of millions of people worldwide. Early detection and treatment in the preliminary stages of eye disease can prevent vision loss for a significant number of people. Finding an effective and simple tool in the early stages of the disease's development is a game changer. This is the objective of said feasibility study and research, endeavoring to detect retinal disease through human tear sampling.*"

About BioLight Life Sciences Ltd.

BioLight manages and invests in companies with a primary focus on bringing vital products to the market in the field of ocular disease and novel treatments in Ophthalmology.

About Alexion, AstraZeneca Rare Disease.

Alexion, AstraZeneca Rare Disease is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders.

Forward-looking statement:



The information, details, and BioLight's estimations contained in this report about the collaboration, trial, and research potential, commencement date of the study and its, execution methods, the results of the study, the collaboration prospects following it, and the approvals required in connection with the aforementioned are "forward-looking information" as defined in the Israeli Securities Law, 1968 which involves high uncertainty and is based, among other things, on third parties and on various variables over which the BioLight does not necessarily have control, and as a result, it is possible that the aforementioned information, details, and estimates, in practice, will not be realized and/or will not be fully realized and/or will materialize in a way that is fundamentally different from the initial estimations or observations.